Compare EGY & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | CABA |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.3M | 495.7M |
| IPO Year | 1996 | 2019 |
| Metric | EGY | CABA |
|---|---|---|
| Price | $4.99 | $3.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.30 | ★ $14.50 |
| AVG Volume (30 Days) | 1.4M | ★ 5.2M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $359,272,000.00 | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $29.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $1.26 |
| 52 Week High | $6.72 | $4.23 |
| Indicator | EGY | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 46.57 |
| Support Level | $4.55 | $2.74 |
| Resistance Level | $5.69 | $3.34 |
| Average True Range (ATR) | 0.20 | 0.22 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 21.24 | 52.46 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.